Clozapine Rems Patient Status Form. Web the patient status form may be submitted online or via a fax. Web the clozapine rems (risk evaluation and mitigation strategy) is a safety program required by the food and drug administration (fda) to manage the risk of severe neutropenia associated with clozapine treatment.
Web patient information to receive treatment, a patient must be enrolled in the clozapine rems program by a certified doctor. A fact sheet is included on changes to the clozapine rems and a new prescriber designee form is available. What you need to know about clozapine and neutropenia with your doctor. Web patient monitoring must continue per the prescribing information. Web how to use the patient status form (continued) beginning november 15, 2021, prescribers must complete and submit the patient status form to the rems for each enrolled patient who is continuing. Web we encourage pharmacists and prescribers to continue working with the clozapine rems to complete certification and prescribers should continue to enroll patients and submit the patient status form. Select the create or add buttons for the appropriate patient. Web the patient status form may be submitted online or via a fax. To submit online, log into your account at www.clozapinerems.com and select themanage patient button. Enroll in the clozapine rems by completing the prescriber enrollment form and submitting it to the clozapine rems.
Web prescribers pharmacies report anc via the website or anc lab reporting form anc reporting frequency is dependent on patient’s monitoring frequency (e.g., weekly, biweekly, monthly)dispensing. To submit online, log into your account at www.clozapinerems.com and select themanage patient button. Enroll in the clozapine rems by completing the prescriber enrollment form and submitting it to the clozapine rems. Web patient information to receive treatment, a patient must be enrolled in the clozapine rems program by a certified doctor. Web the clozapine rems (risk evaluation and mitigation strategy) is a safety program required by the food and drug administration (fda) to manage the risk of severe neutropenia associated with clozapine treatment. Web instead anc results will be submitted monthly through a new patient status form. Web we encourage pharmacists and prescribers to continue working with the clozapine rems to complete certification and prescribers should continue to enroll patients and submit the patient status form. Severe neutropenia (absolute neutrophil count (anc) less than 500/µl), can lead to serious and fatal infections. Web the patient status form may be submitted online or via a fax. Web how to use the patient status form (continued) beginning november 15, 2021, prescribers must complete and submit the patient status form to the rems for each enrolled patient who is continuing. Web prescribers pharmacies report anc via the website or anc lab reporting form anc reporting frequency is dependent on patient’s monitoring frequency (e.g., weekly, biweekly, monthly)dispensing.
